Cellective BioTherapy

What Cellective BioTherapy does

Cellective BioTherapy, Inc. is a preclinical-stage biotechnology company founded in 2015 as a spinout from Duke University, headquartered in Research Triangle Park, North Carolina. The company is developing first-in-class regulatory B10 cell-based immunotherapies built around two complementary modalities: a monoclonal antibody platform that selectively depletes regulatory B10 cells to enhance immune responses (positioned as a complement to checkpoint inhibitors in oncology), and an autologous cellular therapy platform that expands human regulatory B10 cells ex vivo to suppress aberrant immune responses in autoimmune disease, chronic graft-versus-host disease (cGVHD), severe combined immunodeficiency (SCID), and transplantation. The platform is anchored by an IP portfolio exclusively licensed from Duke University and by founder Thomas F. Tedder, who holds 25 issued U.S. patents in B cell biology.

The company addresses patient populations across oncology, autoimmunity, immunodeficiency, cGVHD, and infectious disease, with an initial strategic focus on orphan indications (SCID, cGVHD) intended to enable accelerated regulatory pathways before expanding into larger disease areas. Target users are ultimately patients with immunological diseases, but commercially the company pursues strategic partnerships with pharmaceutical companies for checkpoint-inhibitor combinations and broader market access rather than direct commercialization.

Cellective BioTherapy is privately held, has 1-10 employees, and is pre-revenue. The company has raised a single disclosed $2.5 million seed round in 2015 led by Eshelman Ventures (Fred Eshelman). Its anticipated revenue model is based on one-time licensing, partnerships, and eventual product commercialization. Marketing and distribution activities are limited to the corporate website, newsletter outreach, and periodic conference participation (e.g., 2018 CED Life Science Conference). Leadership comprises founder/CEO Thomas F. Tedder, PhD, and CFO/Director Robert J. Bonczek, JD, MBA, supported by an IP counsel and senior pharmaceutical advisors drawn from prior public biotech and large-pharma roles.

Name

Cellective BioTherapy

Legal name

Cellective BioTherapy, Inc.

Website

https://cellectivebiotherapy.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Cellective BioTherapy is a preclinical-stage Duke University spinout developing first-in-class regulatory B10 cell-based immunotherapies - monoclonal antibody depletion and autologous cellular expansion platforms - to treat cancer, autoimmune disease, immunodeficiency, and chronic graft-versus-host disease.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Dendritic Cell & Other APC-based Therapies (HLAAABAF)

Keywords

• Immunotherapy development
• Monoclonal antibody therapy
• Cell therapy platforms
• Cancer immunotherapy
• Autoimmune disease treatment

Headquarters

HQ city

Raleigh

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Others

Revenue model

1. Biopharmaceutical Development: Pre-revenue preclinical stage company developing first-in-class regulatory B10 cell-based immunotherapies. Revenue generation anticipated through licensing, partnerships, and eventual product commercialization.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Cellective BioTherapy develops first-in-class regulatory B10 cell-based immunotherapies consisting of two complementary technology platforms: a monoclonal antibody-based B10 cell depletion platform that enhances immune responses against cancer, and an autologous B10 cell expansion platform that suppresses immune responses for treating autoimmune disease, chronic graft-versus-host disease (cGVHD), transplantation, and immunodeficiency. The company is preclinical-stage and has not yet commercialized any products.

Product overview

Cellective BioTherapy is developing a proprietary regulatory B10 cell-based immunotherapy platform consisting of two complementary technologies: (1) a monoclonal antibody platform for targeted B10 cell depletion to enhance immune responses against cancer, and (2) an autologous cellular therapy platform for B10 cell expansion to suppress immune responses in autoimmune diseases, cGVHD, and immunodeficiency. The platform is designed to address unmet clinical needs in oncology, autoimmunity, and transplantation through first-in-class cell-based immunotherapies.

Differentiator

Problem solved

Functional benefit

Products and services

• B10 Cell Depletion Technology (mAb-induced B10 Cell Depletion) Monoclonal antibody technology that depletes regulatory B10 cells without destroying other essential B cells, enhancing patient immune response to cancer and complementing existing immunotherapies. Designed as a combination partner for checkpoint inhibitor regimens in solid tumors and as an adjuvant for vaccines and infection response.
• B10 Cell Expansion Technology Cellular immunotherapy technology that expands human regulatory B10 cells ex vivo for autologous use, designed to treat autoimmune disease, chronic graft-versus-host disease (cGVHD), transplantation complications, and immunodeficiency conditions including SCID.
• Regulatory B10 Cell-Based Immunotherapy Platform Proprietary platform combining the company's two B10 cell-based technologies that can either enhance or inhibit immune responses as needed for disease treatment. Indication areas include cancer, autoimmunity, immunodeficiency, inflammation, solid tumors, and infection.

Quantifiable outcome

• SCID affects 40-100 babies born in the U.S. each year
• +1 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Duke UniversitycoreStrategic or Co-development Partner · 1 January 2015Cellective's technologies and comprehensive IP portfolio were licensed exclusively from Duke University. The company was founded as a Duke University spinout in 2015. Dr. Thomas Tedder, founder and CEO, was the inaugural chairman and professor of Duke University Medical Center's Department of Immunology.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Adaptimmune Therapeutics: Clinical-stage cell therapy company developing SPEAR T-cell receptor (TCR) therapies for solid tumors. Comparable as an established cell therapy company in the immunotherapy space where Cellective BioTherapy also operates.
• AstraZeneca (MedImmune): Major pharma with checkpoint inhibitor Imfinzi and cell therapy capabilities. Acquired Dr. Tedder's prior company Cellective Therapeutics in 2005, making it a natural strategic acquirer or partner for Cellective BioTherapy given prior relationship.
• Allogene Therapeutics: Clinical-stage cell therapy company developing allogeneic CAR-T therapies for cancer. Comparable as a leading cell therapy company pursuing combination immunotherapy strategies, though focused on allogeneic T cells rather than autologous B cell therapies.
• Bristol-Myers Squibb: Major pharma with leading checkpoint inhibitor franchise (Opdivo) and active cell therapy business (Breyanzi, Abecma). Cellective BioTherapy plans to partner with checkpoint inhibitor leaders — BMS is a likely target partner and direct incumbent in the immuno-oncology space.

Direct peers

• Cellectis: Clinical-stage cell therapy company developing engineered CAR-T and allogeneic cell therapies. Comparable to Cellective BioTherapy in developing novel cell-based immunotherapies from a similar cell therapy foundation, though focused on engineered T cells rather than regulatory B cells.

Emerging players

• Jasper Therapeutics: Clinical-stage biotechnology developing novel antibody-based therapies for immunology and oncology, including cell therapy conditioning. Comparable as a small-cap biotech targeting immune system modulation in both hematologic and autoimmune indications.
• Kyverna Therapeutics: Clinical-stage cell therapy company developing CAR-T therapies for autoimmune diseases. Highly comparable — addresses the same autoimmune cell therapy thesis that Cellective BioTherapy pursues through B10 cell expansion technology.
• Evelo Biosciences: Clinical-stage immunology company developing oral biologics that act on the gut-associated immune system for autoimmune and inflammatory diseases. Comparable as an early-stage immunology platform company pursuing novel mechanisms for immune modulation.
• Nkarta: Clinical-stage cell therapy company developing engineered NK cell therapies for cancer and autoimmune diseases. Comparable as a novel cell therapy company with a pipeline addressing both oncology and autoimmune indications — overlapping with Cellective BioTherapy's dual-platform approach.
• Fate Therapeutics: Clinical-stage cell therapy company developing off-the-shelf NK and T-cell cancer immunotherapies from iPSC platform. Comparable as a novel cell therapy platform company pursuing multiple hematologic and solid tumor indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/cellective-biotherapy-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellective BioTherapy